WO2012020767A1 - ピロロキノリンキノンのゲル - Google Patents
ピロロキノリンキノンのゲル Download PDFInfo
- Publication number
- WO2012020767A1 WO2012020767A1 PCT/JP2011/068181 JP2011068181W WO2012020767A1 WO 2012020767 A1 WO2012020767 A1 WO 2012020767A1 JP 2011068181 W JP2011068181 W JP 2011068181W WO 2012020767 A1 WO2012020767 A1 WO 2012020767A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gel
- salt
- pyrroloquinoline quinone
- mixture
- solubility
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Definitions
- the present invention relates to a gel containing pyrroloquinoline quinone and a method for producing the same.
- PQQ Pyrroloquinoline quinone
- Non-Patent Document 1 Pyrroloquinoline quinone
- PQQ is present not only in bacteria but also in eukaryotic molds and yeasts, and plays an important role as a coenzyme.
- PQQ there are many cell growth promoting effects, anti-cataract effects, liver disease desired treatment effects, damage healing effects, anti-allergic effects, reverse transcriptase inhibitory effects and glyoxalase I inhibitory-anticancer effects by the recent years.
- Physiological activity has been elucidated.
- Non-patent Document 2 a crude PQQ product obtained by an organic chemical synthesis method (Non-patent Document 2) or a fermentation method (Patent Document 1) to chromatography, concentrating the PQQ section in the effluent, It can be obtained by crystallization by precipitation and drying (Patent Document 2).
- Patent Document 3 The crystal structure of this PQQ salt has been reported (Non-patent Document 3).
- gelling agents used in the food and pharmaceutical fields are high molecular weight substances such as collagen, hyaluronic acid, agar, and carrageenan.
- gelling agents that gel even with low molecular compounds have been reported (Non-patent Documents 4 and 5).
- Non-patent Documents 4 and 5 there is no known low-molecular gelling agent that can be used in foods.
- many polymer gelling agents are dissolved by heating and are often formed by cooling.
- the present inventors mixed a pyrroloquinoline quinone salt and a dispersion medium at room temperature, and lowered the temperature of the resulting mixture by 10 ° C. or more to form a gel in which the pyrroloquinoline quinone salt forms a fibrous structure. It was found that can be obtained.
- the salt of pyrroloquinoline quinone can form a gel without being dissolved in a dispersion medium (solvent) under predetermined conditions. The present invention is based on this finding.
- the present invention is to provide a gel containing pyrroloquinoline quinone that can be easily gelled around room temperature and can be used in the food field, and a method for producing the same.
- a gel comprising a salt of pyrroloquinoline quinone.
- a pharmaceutical comprising the gel according to any one of (1) to (9), the dried body according to (10), or the fibrous structure according to (11).
- a cosmetic comprising the gel according to any one of (1) to (9), the dried product according to (10), or the fibrous structure according to (11).
- a gelling agent comprising a salt of pyrroloquinoline quinone.
- the gel of the present invention is a novel low molecular gel that can be eaten.
- a water-containing gel using PQQ can be provided.
- gelation can be performed at room temperature or lower, which is advantageous in that treatment such as heating is not necessary.
- it is advantageous in that it can provide a PQQ-containing liquid that becomes uniform even at a high concentration by gelation.
- this gel has a different dissolution rate from the same amount of crystals and can control the solubility, so that it is used for foods, functional foods, pharmaceuticals, quasi drugs, cosmetics, etc. This is advantageous in that it can be done.
- FIG. 1 shows an optical micrograph of a raw material PQQ disodium salt crystal.
- FIG. 2 shows the result of X-ray diffraction of the raw material PQQ disodium salt crystal.
- FIG. 3 shows an optical micrograph of a 1% gel.
- FIG. 4 shows the X-ray diffraction of a 1% gel.
- FIG. 5 shows an optical micrograph of a 2% gel.
- FIG. 6 shows a photograph of a molded product with 5% gel.
- FIG. 7 shows an optical micrograph of 5% gel.
- FIG. 8 shows the X-ray diffraction of a 5% gel.
- FIG. 9 shows the X-ray diffraction of the gel lyophilized product.
- FIG. 10 shows an optical micrograph of a freeze-dried gel product.
- FIG. 11 shows a scanning electron micrograph of a solid obtained by drying a 1% gel after washing with ethanol.
- a gel containing a pyrroloquinoline quinone salt can be produced by reducing the solubility of the pyrroloquinoline quinone salt in a mixture of the pyrroloquinoline quinone salt and the dispersion medium.
- a gel containing a salt of pyrroloquinoline quinone is a gel substantially composed of a salt of pyrroloquinoline quinone and a dispersion medium.
- the salts of pyrroloquinoline quinone associate with each other to form a fibrous structure, and a dispersion medium is contained in the fibrous structure.
- fibrous structure means a three-dimensional network structure formed by physical crosslinking of an aggregate formed by self-association of a pyrroloquinoline quinone salt by an interaction other than a covalent bond. That is, the gel of the present invention can be said to be a physical gel.
- Non-covalent bonds include non-covalent bonds such as hydrogen bonds, ionic bonds, coordination bonds, ⁇ - ⁇ interactions (stacking), and hydrophobic interactions. It is.
- the salt of pyrroloquinoline quinone used in the present invention is a salt of the structural formula represented by the following formula (1).
- Examples of the salt of pyrroloquinoline quinone used in the present invention include alkali metal salts, alkaline earth metal salts, and ammonium salts of pyrroloquinoline quinone, with alkali metal salts being preferred.
- the salt of pyrroloquinoline quinone may be used alone or in combination.
- alkali metal salt of pyrroloquinoline quinone used in the present invention examples include sodium, potassium, lithium, calcium, magnesium, cesium, rubidium and the like. Preferably, it is a sodium salt.
- the substitution number of the salt in the alkali metal salt of pyrroloquinoline quinone is 1 to 3, and any of a monoalkali metal salt, a dialkali metal salt, and a trialkali metal salt is preferable, but a dialkali metal salt is preferable.
- a disodium salt is particularly preferable.
- Disodium salt which is a needle-like crystal having a crystal structure represented by 9.1, 10.3, 13.8 ⁇ 0.4 ° at 2 ⁇ peaks using Cu K ⁇ radiation by powder X-ray diffraction as a raw material used Is preferred.
- the crystallinity of the pyrroloquinoline quinone salt can be 0 to 100%, preferably 20 to 100%.
- pyrroloquinoline quinone salt used in the present invention a commercially available salt can be obtained, and it can be produced by a known method.
- the present invention is characterized in that PQQ itself can be gelled from a salt of PQQ and a dispersion medium (water), and can be produced without using a normal gelling agent. it can.
- the gel is formed by the fibrous polymer chain spreading throughout the solution and holding the liquid.
- Well-known examples are agar and collagen, where polymer chains retain water.
- PQQ is a low-molecular substance and needs to be in a fibrous form before gelation.
- PQQ is thought to be a fiber with molecular chains spread by noncovalent bonds.
- the gelation method using this non-covalent bond is easily changed depending on conditions such as salt concentration, precursor, temperature, etc., the gel of the present invention can be produced as follows.
- a gel comprising a pyrroloquinoline quinone salt can be produced by mixing a pyrroloquinoline quinone salt and a dispersion medium and reducing the solubility of the pyrroloquinoline quinone salt in the resulting mixture.
- the temperature and pH of the mixture can be adjusted.
- a pyrroloquinoline quinone salt and a dispersion medium are mixed, and the resulting mixture has a fibrous structure formed by associating pyrroloquinoline quinone salts with each other by lowering the temperature of the mixture by 10 ° C. or more.
- a gel can be produced.
- a gel having a fibrous structure formed by mixing pyrroloquinoline quinone salts with each other is prepared by mixing a pyrroloquinoline quinone salt and a dispersion medium and lowering the pH of the resulting mixture by 2 or more. be able to.
- this fibrous structure becomes a solid gel containing a solvent.
- the present invention is basically gelled in water, it is possible to replace the water contained in this gel with another. There is no problem even if the liquid is replaced with ethanol, propanol, butanol, oil or fat.
- a water-containing gel but also a gel containing an organic solvent can be used.
- examples of the dispersion medium used in the present invention include water, organic solvents (for example, ethanol, propanol, butanol, glycerin, propylene glycol, and the like), oils and fats, and the like, preferably water.
- the dispersion medium is water, it can be a hydrous gel (hydrogel).
- the mixing of the pyrroloquinoline quinone salt and the dispersion medium may be performed by adding the pyrroloquinoline quinone salt to the dispersion medium, adding the dispersion medium to the pyrroloquinoline quinone salt, or alternatively,
- the salt of pyrroloquinoline quinone and the dispersion medium may be added to separate containers, but preferably the salt of pyrroloquinoline quinone can be added to the dispersion medium.
- the concentration of the pyrroloquinoline quinone salt is preferably equal to or higher than the solubility.
- “solubility” means the limit of solute dissolution in a solvent, and can be represented by the concentration of the solute in the saturated solution.
- the solubility of the salt of pyrroloquinoline quinone can be appropriately determined depending on the temperature of the mixture.
- the solubility of pyrroloquinoline quinone disodium is 0.299 g per 100 g of water at 25 ° C.
- the weight concentration of the pyrroloquinoline quinone salt is preferably 0.5 to 70% by weight, more preferably 0.7 to 20% by weight. If it is less than this concentration, it will dissolve and not gel in the case of pure water. Further, if the concentration is higher than this range, it becomes clayy and it cannot be determined whether or not a gel state is formed. In order to increase the content of PQQ, it is possible to form a gel with a high concentration by adding a solid PQQ salt after gelation.
- the weight concentration of the pyrroloquinoline quinone salt is preferably 0.7 to 20% by weight, more preferably 0.7 to 10% by weight when the temperature of the mixture is 20 to 50 ° C.
- the pyrroloquinoline quinone salt and the dispersion medium can be mixed at ⁇ 30 to 150 ° C.
- the temperature of the mixture can be 20-50 ° C, more preferably 20-40 ° C, and even more preferably 20-30 ° C.
- the pH of the obtained mixture can be adjusted to pH 2-10.
- the obtained mixture may be stirred.
- Stirring can be carried out by subjecting to magnetic stirring, mechanical stirring, manual stirring, shaking stirring, etc., preferably mechanical stirring, manual stirring, and shaking stirring.
- the temperature of the obtained mixture can be -20 to 100 ° C, more preferably -10 to 50 ° C. Increasing the temperature increases the solubility of PQQ and increases the amount of PQQ required to form gelled fibers. In addition, when the temperature is too low, the solubility of PQQ is too low, and the structural transformation necessary for fibrosis becomes slow. Further, the water freezes and gelation does not occur.
- the temperature of the obtained mixture can be lowered from the original temperature by 10 ° C. or more, preferably 15 ° C. or more, more preferably 20 ° C. or more.
- the temperature of the resulting mixture can also be lowered from the original temperature by 10 to 120 ° C., preferably 15 to 50 ° C.
- the temperature of the mixture can be, for example, ⁇ 20 to 20 ° C. Preferably, it can be ⁇ 15 to 15 ° C., more preferably ⁇ 10 to 10 ° C.
- the method for lowering the temperature of the mixture is not particularly limited.
- the temperature can be lowered by placing the mixture in a refrigerator.
- the mixture with the temperature lowered may be stirred.
- Stirring can be carried out by subjecting to magnetic stirring, mechanical stirring, manual stirring, shaking stirring, etc., preferably mechanical stirring, manual stirring, and shaking stirring.
- the mixture with the temperature lowered can be left as it is.
- the time can be 0.5 minutes to 2 weeks, preferably 30 minutes to 1 week.
- the pyrroloquinoline quinone salt and the dispersion medium can be mixed at a pH of 2 to 10.
- the temperature of the obtained mixture can be ⁇ 30 to 150 ° C., preferably 20 to 100 ° C.
- the obtained mixture may be stirred.
- Stirring can be carried out by subjecting to magnetic stirring, mechanical stirring, manual stirring, shaking stirring, etc., preferably mechanical stirring, manual stirring, and shaking stirring.
- the pH of the obtained mixture can be adjusted to pH 2-4. That is, the pH of the obtained mixture can be lowered from the original pH by 0.1 or more, preferably 0.2 or more, more preferably 0.3 or more. Since the solubility of the salt of pyrroloquinoline quinone can be decreased by changing the pH of the mixture (in particular, changing from pH 6 to 10 in the range of pH 2 to 4), the gel of the present invention can be produced.
- the method for lowering the pH of the mixture is not particularly limited, and can be adjusted using, for example, an acidic substance (for example, hydrochloric acid) or an alkaline substance (for example, sodium hydroxide).
- the mixture with lowered pH may be stirred.
- Stirring can be carried out by subjecting to magnetic stirring, mechanical stirring, manual stirring, shaking stirring, etc., preferably mechanical stirring, manual stirring, and shaking stirring.
- the mixture with lowered pH can be left as it is.
- the time can be 0.5 minutes to 2 weeks, preferably 30 minutes to 1 week.
- the gel of the present invention can thus be formed by linking fibers between molecules, and the formation can be performed at room temperature. Unlike conventional gelling agents such as agar, it does not need to be heated and melted.
- PQQ molecules are formed by ionic bonds or hydrogen bonds with alkali metals.
- concentration of PQQ is high, the original crystal structure is mixed in addition to the fiber structure that gels, but there is no particular problem if gelation occurs. Moreover, there is no problem even if PQQ powder is mixed with the substance once gelled.
- Non-Patent Document 3 indicates that there is an intermolecular hydrogen bond or ionic bond in the disodium salt of PQQ, and the stacking of aromatic rings is also expected.
- the fiberized PQQ has a structure different from that of a crystal, it is considered that a short repeating unit has a similar structure, and it is considered that an intermolecular bond is formed by the above-described intermolecular interaction.
- the following formula (2) describes some of the expected connections between molecules.
- the weight concentration of the pyrroloquinoline quinone salt is preferably 0.5 to 70% by weight, more preferably 0.7 to 20% by weight, even more preferably, based on the total gel weight. Is 0.7 to 10% by weight.
- the gel of the present invention has a slower dissolution rate than the original crystal, and the dissolution rate can be changed only by performing a gelation operation without mixing a solubility control substance with PQQ. This is very effective as an advantage of suppressing denaturation and a technique of gradually releasing when mixed with other materials. This property is presumed to be due to the structure in which the PQQ molecule arrangement is hardly water-soluble during fiber formation.
- the gel of the present invention can be used with a sustained release substrate.
- the gel of the present invention can also control the dissolution rate by adjusting the pH.
- the gel of the present invention can suppress dissolution under acidic conditions and can proceed with dissolution under neutral conditions.
- a pyrroloquinoline produced by lowering the temperature of a mixture of a pyrroloquinoline quinone sodium salt and a dispersion medium at 20 to 40 ° C. by 10 ° C. or more to ⁇ 10 to 10 ° C.
- a gel comprising a sodium salt of quinone and a method for producing the gel.
- the weight concentration of the sodium salt of pyrroloquinoline quinone in the mixture is preferably 0.7 to 20% by weight, more preferably 0.7 to 10% by weight.
- the pyrrolo produced by lowering the temperature of the mixture of the pyrroloquinoline quinone sodium salt and the dispersion medium, which is 20 to 40 ° C., to ⁇ 10 to 10 ° C. by 20 ° C. or more.
- a gel comprising a sodium salt of quinoline quinone and a method for producing the gel.
- the weight concentration of the sodium salt of pyrroloquinoline quinone in the mixture is preferably 0.7 to 20% by weight, more preferably 0.7 to 10% by weight.
- a fibrous structure (fibrous substance) made of PQQ salt can be produced by drying the gel of the present invention.
- the fibrous structure of the present invention can be produced by drying the gel of the present invention by a method such as freeze-drying, spray-drying, solvent substitution and heat drying.
- the solid produced by drying this gel has a large surface area and is characterized by a fibrous shape, which is a substance that has a texture and appearance that is different from a normal powder, and is important in the fields of food, cosmetics and medicine. It can also be cast on a plate to form a film.
- the fiber thickness of the fibrous structure of the present invention is 0.02 to 2000 ⁇ m, preferably 0.05 to 500 ⁇ m, more preferably 0.05 to 50 ⁇ m, and still more preferably 0.05 to 5 ⁇ m. can do.
- the thickness of the fiber can be measured using a microscope (an electron microscope, an optical microscope, a probe, etc.).
- the gel of the present invention can be mixed with sweeteners used in ordinary gel foods.
- sweeteners monosaccharides, disaccharides, oligosaccharides, and artificial sweetener sugars can be mixed. Examples include fructose, glucose, galactose, sorbitol, xylitol, erythritol, trehalose, palatinit, aspartame, acesulfame K, sucralose, licorice extract, lacanca syrup, and honey.
- Flavor, acidulant, salt, umami ingredient, fruit juice, fermented food, lipid, moisturizer, whitening agent, herbal extract, tea, coffee, emulsifier, glycerin, preservative, antibacterial agent, steroid, methyl salicylate, vitamin, indomethacin, etc. are required Add them according to your needs.
- a gelling agent comprising a salt of pyrroloquinoline quinone can be provided.
- a gel comprising a salt of pyrroloquinoline quinone.
- the gel according to (1) wherein the salt of pyrroloquinoline quinone is 0.5 to 70% by weight.
- the gel according to any one of (1) to (3) which contains a sweetener.
- the gel according to any one of (1) to (4) which contains a polymer gelling agent.
- a fibrous substance comprising a salt of pyrroloquinoline quinone.
- a method for producing a gel comprising a salt of pyrroloquinoline quinone characterized by adding a salt of pyrroloquinoline quinone to water and stirring at 20 to 100 ° C, followed by cooling to 10 ° C or more or lowering the pH.
- a food containing the gel according to any one of (1) to (5) A food containing the gel according to any one of (1) to (5).
- a drug comprising the gel according to any one of (1) to (5).
- a cosmetic comprising the gel according to any one of (1) to (5).
- a medicine containing the fibrous substance according to (6) (12) A medicine containing the fibrous substance according to (6).
- a cosmetic comprising the fibrous material according to (6).
- powder X-ray diffraction (hereinafter referred to as XRD) is M18XCE manufactured by Mac Science Co., Ltd., Cu / tube voltage 40 kV / tube current 100 mA, divergence slit: 1 °, scattering slit: 1 ° , Receiving slit: 0.3 mm, scan speed: 4.000 ° / min, sampling width: 0.020 °.
- the optical micrographs were taken with a NIKON microscope TE-2000S and a 40 ⁇ objective lens.
- UV measurement was performed using a HITACHI U-2000 Spectrophotometer.
- Comparative Example 1 Raw material pyrroloquinoline quinone disodium pyrroloquinoline quinone disodium (manufacturer: Mitsubishi Gas Chemical Co., Inc., powder) was used. The result of observing pyrroloquinoline quinone disodium with an optical microscope is shown in FIG. The pyrroloquinoline quinone disodium used was a needle-like crystal and was found to be shorter than the gelled one (FIG. 1 and FIG. 3 described later). It was also found that it is a crystalline substance and is different from that forming a gel. The result of measuring pyrroloquinoline quinone disodium by XRD is shown in FIG. It was found to be a needle-like crystal having a crystal structure represented by 9.1, 10.3, 13.8 ⁇ 0.4 ° at 2 ⁇ peaks using Cu K ⁇ radiation.
- Example 1 0.1 g of PQQ powder of 1% gel comparative example 1 was added to a 15 ml plastic centrifuge container, 10 ml of water was added, and the mixture was shaken at room temperature (about 25 ° C.). This was cooled in a refrigerator to 4 ° C., and then shaken and mixed. When stored in the refrigerator overnight, the whole turned into a uniform gel. The result of observation with an optical microscope is shown in FIG. It changed to a fiber shape that was longer than the original needle shape (FIGS. 1 and 3).
- the gel was formed into a gel capable of holding the liquid by changing from a crystal to an amorphous structure in the gelation. Moreover, precipitation of PQQ solid was not seen by becoming a gel state, but it was uniform as a whole.
- Example 2 2% gel The same operation as in Example 1 was performed. 0.2 g of the PQQ powder of Comparative Example 1 was added to a 15 ml plastic centrifuge container, 10 ml of water was added, and the mixture was shaken at room temperature (about 25 ° C.). This was cooled in a refrigerator to 4 ° C., and then shaken and mixed. When stored in the refrigerator overnight, the whole turned into a uniform gel. The result of observation with an optical microscope is shown in FIG. Fine fibers were formed. The fiber density increased as the concentration increased ( Figure 3)
- Example 3 5% gel The same operation as in Example 1 was performed. 0.5 g of PQQ powder of Comparative Example 1 was added to a 15 ml plastic centrifuge container, 10 ml of water was added, and the mixture was shaken at room temperature (about 25 ° C.). This was cooled in a refrigerator to 4 ° C., and then shaken and mixed. When stored in the refrigerator overnight, the whole turned into a uniform gel. This was taken out from the container, cut into an appropriate length, put into a 9 cm petri dish, and the result of observation was shown in FIG. The gel was strong enough to maintain its shape. Further, as can be seen from the photograph, the gel became uniform as a whole, with no solid (PQQ) precipitated.
- FIG. It was found to have a dense fibrous structure.
- the result of measurement by XRD is shown in FIG. A peak derived from the original crystal structure was present together with an 8.3 ° peak similar to that in Example 1. That is, it was a gel in which the original crystal structure was slightly mixed with the fibrosis necessary for gelation. In the optical microscope, the original crystals are hardly mixed, and it is considered that the fibrous substance contains a structure close to the original crystals.
- Example 4 Ethanol gel When the 5% gel prepared in Example 3 was dropped into a large excess of ethanol, the gel state was maintained. Ethanol penetrated into the interior by exchange by diffusion.
- Example 5 Addition of sweetener When 10% of sorbitol was added as a powder to the 2% gel synthesized in Example 2, the gel structure was maintained and a gel having a sweetener could be prepared.
- Example 6 and Comparative Example 2 Dissolution Test As Comparative Example 2, using the PQQ powder of Comparative Example 1 which is a raw material used in each Example, 1.3 mg of the PQQ powder was put in an acrylic cell for UV measurement. An additional 2 ml of water was added. As Example 6, 27 mg of the 5% gel prepared in Example 3 (corresponding to 1.35 mg of PQQ powder) was placed in an acrylic cell for UV measurement, and 2 ml of water was further added. Dissolution in water was followed at 450 nm absorption at room temperature. Absorbance measurement was performed for 1 hour, and the time from the slope of the concentration change until it completely dissolved was calculated. The results are shown in Table 1.
- the dissolution rate of PQQ can be suppressed by gelation. From this, the PQQ gel can be expected to have an effect of suppressing reaction with other food ingredients. Moreover, according to this method, the solubility can be controlled without requiring a special coating technique or substance.
- Examples 7 and 8 pH responsiveness (model of biological solubility) It was tested how the dissolution rate of the 5% gel changes with pH in the same manner as the solubility test of Example 6. Experiments were performed using artificial gastric juice and artificial intestinal fluid. The results are shown in Table 2. When artificial gastric juice was added, it did not dissolve beyond the amount initially dissolved, and the concentration in the solution did not increase. On the other hand, when artificial intestinal fluid was added, the amount of dissolution increased linearly and dissolved immediately upon stirring. From the above, it was found that the gel of the present invention is a gel whose dissolution rate changes with pH. It was also found that the gel of the present invention does not dissolve in water or gastric juice but dissolves in the intestine. This is preferable for oral administration because it does not dissolve in the stomach but dissolves in the intestine, so that it can avoid reaction with unnecessary food ingredients and has a property of dissolving in the intestine where absorption is performed. .
- Example 9 Production of dried gel product The 1% gel prepared in Example 1 was frozen at 80 ° C. This was dried with a freeze dryer (model: EYELA FDU2100, manufacturer: Tokyo Rika Instruments) for 2 days, and finally decompressed to 8 pa, a fibrous solid was obtained. The result of measuring this individual by XRD is shown in FIG. 9, and the result of observation with an optical microscope is shown in FIG. The dried gel was found to be a solid that maintained the fibrous structure of the gel.
- Example 10 and Comparative Example 3 Specific Surface Area Measurement
- the powder of Comparative Example 1 and the 1% gel dried product of Example 9 were dried at 150 ° C. for 20 hours using Quantachrome Instruments AUTOSORB DEGASSER as a pretreatment.
- Quantachrome Instruments Autosorb-6B was used as a measuring apparatus, and the specific surface area was obtained by BET method with N 2 adsorption.
- the powder of Comparative Example 1 was 2.9 m 2 / g
- the fibrous solid of the 1% gel dried product of Example 9 was 7 m 2 / g. From the above, it has been found that the surface area is increased by becoming fibrous.
- a solid having a large surface area could be produced. Thereby, a fibrous solid can be made.
- Comparative Example 4 0.5 g of PQQ powder of Comparative Example 1 was added to a 15 ml plastic centrifuge container, 10 ml of water was added, and the mixture was shaken at room temperature (about 25 ° C.). After 30 minutes at room temperature, the mixture became a heterogeneous solution due to the precipitation of the raw material crystals.
- Example 12 Observation with an electron microscope The 1% gel prepared in Example 1 was washed with a large excess of ethanol, and after removing water, it was cast into an aluminum foil. This was dried under reduced pressure to obtain non-woven PQQ. This was observed with an S-3400N scanning electron microscope manufactured by Hitachi High-Tech. The result is shown in FIG. The thickness of the fibers was 0.15 to 1.5 ⁇ m, and most were thin fibers of 1 ⁇ m or less.
- Example 13 0.01 g of agar (trade name: agarose (low electroosmosis), manufacturer: Nacalai Tex Co., Ltd.) was added to 10 ml of water and dissolved in a microwave oven. After cooling to about 40 ° C., 1 ml each of the 1% gel prepared in Example 1 was mixed. Cooled in the refrigerator overnight. It was gelled and fibers could be confirmed with an optical microscope.
- agar trade name: agarose (low electroosmosis), manufacturer: Nacalai Tex Co., Ltd.
- Example 14 0.01 g of gelatin (trade name: Zerice, manufacturer: Nitta Gelatin Co., Ltd.) was added to 10 ml of water at 75 ° C. and dissolved. After cooling to about 40 ° C., 0.5 ml each was mixed with the 1% gel prepared in Example 1. Cooled in the refrigerator overnight. It was gelled and fibers could be confirmed with an optical microscope.
- gelatin trade name: Zerice, manufacturer: Nitta Gelatin Co., Ltd.
- Comparative Example 5 0.01 g of agar and 0.01 g of PQQ disodium of Comparative Example 1 were added to 10 ml of water and heated using a microwave oven until boiling. At this time, PQQ disodium was completely dissolved. When this was cooled, it gelled. As a result of observation with an optical microscope, the red layer of PQQ was spherically dispersed in the agar, and the fiber structure was lost. From the above, it was found that this gel was gelled by agar and PQQ was not involved in gelation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Jellies, Jams, And Syrups (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
(1)ピロロキノリンキノンの塩を含んでなる、ゲル。
(2)ピロロキノリンキノンの塩が、互いに会合して繊維状構造を形成することを特徴とする、(1)に記載のゲル。
(3)ピロロキノリンキノンの塩が、全ゲル重量に対して、0.5~70重量%である、(1)または(2)に記載のゲル。
(4)塩が、ナトリウム塩である、(1)~(3)のいずれかに記載のゲル。
(5)ピロロキノリンキノンの塩と分散媒との混合物において、ピロロキノリンキノンの塩の溶解度を下げることにより製造される、(1)~(4)のいずれかに記載のゲル。
(6)混合物の溶解度を下げることが、混合物の温度を10℃以上下げることにより行われる、(5)に記載のゲル。
(7)混合物の溶解度を下げることが、混合物のpHを0.1以上下げることにより行われる、(5)に記載のゲル。
(8)甘味料をさらに含んでなる、(1)~(7)のいずれかに記載のゲル。
(9)高分子ゲル化剤をさらに含んでなる、(1)~(8)のいずれかに記載のゲル。
(10)(1)~(9)のいずれかに記載のゲルの乾燥体。
(11)ピロロキノリンキノンの塩からなる、繊維状構造体。
(12)(1)~(9)のいずれかに記載のゲル、(10)に記載の乾燥体、または(11)に記載の繊維状構造体を含んでなる、食品。
(13)(1)~(9)のいずれかに記載のゲル、(10)に記載の乾燥体、または(11)に記載の繊維状構造体を含んでなる、医薬。
(14)(1)~(9)のいずれかに記載のゲル、(10)に記載の乾燥体、または(11)に記載の繊維状構造体を含んでなる、化粧品。
(15)ピロロキノリンキノンの塩を含んでなる、ゲル化剤。
(16)ピロロキノリンキノンの塩と分散媒との混合物において、ピロロキノリンキノンの塩の溶解度を下げることを含んでなる、ピロロキノリンキノンの塩を含んでなるゲルの製造方法。
(17)混合物の溶解度を下げることが、混合物の温度を10℃以上下げることにより行われる、(16)に記載の製造方法。
(18)混合物の溶解度を下げることが、混合物のpHを0.1以上下げることにより行われる、(16)に記載の製造方法。
-ピロロキノリンキノンのピリジン骨格の窒素原子と、別のピロロキノリンキノンのカルボン酸基の酸素原子との、アルカリ金属を介したイオン結合;
-ピロロキノリンキノンのピリジン骨格の窒素原子と、別のピロロキノリンキノンのキノンの酸素原子との、アルカリ金属を介したイオン結合;
-ピロロキノリンキノンのカルボン酸と別のピロロキノリンキノンのカルボン酸の酸素原子の水素結合;
-ピロロキノリンキノンと芳香環と別のピロロキノリンキノンの芳香環のπ-πスタッキング。
(1)ピロロキノリンキノンの塩から成るゲル。
(2)ピロロキノリンキノンの塩が0.5から70重量%であることを特徴する(1)に記載のゲル。
(3)ピロロキノリンキノンのナトリウム塩から成ることを特徴とする(1)又は(2)に記載のゲル。
(4)甘味料を含有する(1)~(3)のいずれかに記載のゲル。
(5)高分子ゲル化剤を含有する(1)~(4)のいずれかに記載のゲル。
(6)ピロロキノリンキノンの塩から成る繊維状物質。
(7)水にピロロキノリンキノンの塩を加え20から100℃で撹拌した後、10℃以上冷却するか若しくはpHを下げることを特徴とするピロロキノリンキノンの塩から成るゲルの製造方法。
(8)(1)~(5)のいずれかに記載のゲルを含む食品。
(9)(1)~(5)のいずれかに記載のゲルを含む薬。
(10)(1)~(5)のいずれかに記載のゲルを含む化粧品。
(11)(6)に記載の繊維状物質を含む食品。
(12)(6)に記載の繊維状物質を含む薬。
(13)(6)に記載の繊維状物質を含む化粧品。
原料としてピロロキノリンキノンジナトリウム(製造元:三菱ガス化学株式会社、粉末)を使用した。ピロロキノリンキノンジナトリウムを光学顕微鏡で観察した結果を図1に示した。使用したピロロキノリンキノンジナトリウムは針状の結晶であり、ゲル化したものよりも短いことが分かった(図1および後述の図3)。また、結晶性の物質であり、ゲルを形成しているものとは異なっていることが分かった。ピロロキノリンキノンジナトリウムをXRDで測定した結果を図2に示した。Cu Kα放射線を用いた2θのピークで9.1、10.3、13.8±0.4°に代表される結晶構造を有する針状結晶であることが分かった。
比較例1のPQQ粉末0.1gを15mlのプラスチック製遠心分離用容器に加え、水10ml加え、室温で振って混合した(約25℃)。これを冷蔵庫で冷却して4℃になった後、さらに振って混合した。一晩、冷蔵庫に保存すると全体が均一なゲル状に変化した。これを光学顕微鏡で観察した結果を図3に示した。元の針状よりも長くなった繊維状に変化していた(図1および図3)。
実施例1と同様の操作を行った。比較例1のPQQ粉末0.2gを15mlのプラスチック製遠心分離用容器に加え、水10ml加え、室温で振って混合した(約25℃)。これを冷蔵庫で冷却して4℃になった後、さらに振って混合した。一晩、冷蔵庫に保存すると全体が均一なゲル状に変化した。これを光学顕微鏡で観察した結果を図5に示した。細かい繊維が形成されていた。濃度が高くなると繊維密度が高くなった(図3)
実施例1と同様の操作を行った。比較例1のPQQ粉末0.5gを15mlのプラスチック製遠心分離用容器に加え、水10ml加え、室温で振って混合した(約25℃)。これを冷蔵庫で冷却して4℃になった後、さらに振って混合した。一晩、冷蔵庫に保存すると全体が均一なゲル状に変化した。これを容器から取り出し、適当な長さに切って9cmのシャーレに入れて観察した結果を図6に示した。形状を維持できる強固なゲルになっていた。また、写真でもわかるようにゲルは内の固体(PQQ)は沈降しない全体として均一なものになった。
実施例3で作製した5%ゲルを大過剰のエタノール内に落としたところ、ゲル状態は維持されていた。拡散による交換でエタノールが内部に浸透した。
実施例2で合成した2%ゲルに10%分のソルビトールを粉末で加えたところ、ゲル構造は維持され、甘味料を有するゲルを作成することができた。
比較例2として、各実施例で使用した原料である比較例1のPQQ粉末を用い、UV測定用のアクリル製セルに該PQQ粉末1.3mgを入れ、さらに2mlの水を加えた。
実施例6として、実施例3で作製した5%ゲル27mg(PQQ粉末1.35mg相当)をUV測定用のアクリル製セルに入れ、さらに2mlの水を加えた。
室温で450nmの吸収で水への溶解を追跡した。吸光度測定を1時間行い、濃度変化の傾きからすべて溶けるまでの時間を計算した。その結果を表1に示す。
実施例6の溶解性試験と同様の方法で5%ゲルの溶解速度がpHでどのように変化するかを試験した。人工胃液と人工腸液を使用して実験を行った。その結果を表2に示す。
以上のことから、本発明のゲルは、pHにより溶解速度の変化するゲルであることが分かった。また、本発明のゲルは、水や胃液では溶解せず、腸で溶解することがわかった。これは経口投与の場合、胃では溶解せず、腸で溶解するため、不必要な食品成分との反応を避けることができ、また、吸収が行われる腸で溶解する性質を有しており好ましい。
実施例1で作製した1%ゲルを80℃で凍結した。これを凍結乾燥器(機種:EYELA FDU2100、製造元:東京理化器械)で2日間乾燥し、最終的には8paまで減圧したところ、繊維状の固体が出来た。この個体をXRDで測定した結果を図9に、光学顕微鏡で観察した結果を図10にそれぞれ示した。ゲル乾燥物が、ゲルの線維構造を維持した固体であることが分かった。
比較例1の粉末および実施例9の1%ゲル乾燥物に対し、前処理としてQuantachrome Instruments社 AUTOSORB DEGASSERを使用し150℃、20時間乾燥した。測定装置は Quantachrome Instruments社 Autosorb-6Bを使用し、N2吸着でBET法を用いて比表面積を出した。
その結果、比較例1の粉末が2.9m2/gであったのに対し、実施例9の1%ゲル乾燥物の繊維状の固体は7m2/gであった。
以上のことから、繊維状になることで表面積が大きくなることが分かった。本発明のゲルを使用することで表面積の大きな固体を作ることができた。これにより繊維状の固体の作ることができる。
比較例1のPQQ粉末0.5gを15mlのプラスチック製遠心分離用容器に加え、水10ml加え、室温で振って混合した(約25℃)。室温で30分後、混合液は原料結晶が沈降して不均一な溶液になった。
実施例1で作製した1%ゲルを大過剰のエタノールで洗浄し、水を除いた後、アルミホイルにキャストした。これを減圧乾燥して不織布状のPQQを得た。これを日立ハイテク製 S-3400N 走査電子顕微鏡で観察した。その結果を図11に示す。繊維の太さは0.15から1.5μmであり、殆どが1μm以下の細い繊維であった。
寒天(商品名:アガロース(低電気浸透)、製造元:ナカライテクス株式会社)0.01gを水10mlに加え、電子レンジで溶解した。約40℃まで冷却し、実施例1で作成した1%ゲルと1mlずつ混合した。冷蔵庫で1晩冷却した。ゲル化しており、光学顕微鏡で繊維が確認できた。
ゼラチン(商品名:ゼライス、製造元:新田ゼラチン株式会社)0.01gを75℃の水10mlに加え、溶解した。約40℃まで冷却し、実施例1で作成した1%ゲルと0.5mlずつ混合した。冷蔵庫で1晩冷却した。ゲル化しており、光学顕微鏡で繊維が確認できた。
寒天0.01gと比較例1のPQQジナトリウム0.01gを水10mlに加え、電子レンジを用いて沸騰するまで加熱した。この時、PQQジナトリウムは完全に溶解した。これを冷却するとゲル化した。光学顕微鏡で観察した結果、PQQの赤い層は寒天中に球状に分散しており、繊維構造はなくなっていた。以上のことから、このゲルは寒天によるゲル化でPQQはゲル化に関わっていないことが分かった。
Claims (18)
- ピロロキノリンキノンの塩を含んでなる、ゲル。
- ピロロキノリンキノンの塩が、互いに会合して繊維状構造を形成することを特徴とする、請求項1に記載のゲル。
- ピロロキノリンキノンの塩が、全ゲル重量に対して、0.5~70重量%である、請求項1または2に記載のゲル。
- 塩が、ナトリウム塩である、請求項1~3のいずれか一項に記載のゲル。
- ピロロキノリンキノンの塩と分散媒との混合物において、ピロロキノリンキノンの塩の溶解度を下げることにより製造される、請求項1~4のいずれか一項に記載のゲル。
- 混合物の溶解度を下げることが、混合物の温度を10℃以上下げることにより行われる、請求項5に記載のゲル。
- 混合物の溶解度を下げることが、混合物のpHを0.1以上下げることにより行われる、請求項5に記載のゲル。
- 甘味料をさらに含んでなる、請求項1~7のいずれか一項に記載のゲル。
- 高分子ゲル化剤をさらに含んでなる、請求項1~8のいずれか一項に記載のゲル。
- 請求項1~9のいずれか一項に記載のゲルの乾燥体。
- ピロロキノリンキノンの塩からなる、繊維状構造体。
- 請求項1~9のいずれかに記載のゲル、請求項10に記載の乾燥体、または請求項11に記載の繊維状構造体を含んでなる、食品。
- 請求項1~9のいずれかに記載のゲル、請求項10に記載の乾燥体、または請求項11に記載の繊維状構造体を含んでなる、医薬。
- 請求項1~9のいずれかに記載のゲル、請求項10に記載の乾燥体、または請求項11に記載の繊維状構造体を含んでなる、化粧品。
- ピロロキノリンキノンの塩を含んでなる、ゲル化剤。
- ピロロキノリンキノンの塩と分散媒との混合物において、ピロロキノリンキノンの塩の溶解度を下げることを含んでなる、ピロロキノリンキノンの塩を含んでなるゲルの製造方法。
- 混合物の溶解度を下げることが、混合物の温度を10℃以上下げることにより行われる、請求項16に記載の製造方法。
- 混合物の溶解度を下げることが、混合物のpHを0.1以上下げることにより行われる、請求項16に記載の製造方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012528687A JP5884731B2 (ja) | 2010-08-09 | 2011-08-09 | ピロロキノリンキノンのゲル |
US13/814,820 US9012521B2 (en) | 2010-08-09 | 2011-08-09 | Pyrroloquinoline quinone gel |
CN201180038175.6A CN103052391B (zh) | 2010-08-09 | 2011-08-09 | 吡咯并喹啉醌的凝胶 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-178349 | 2010-08-09 | ||
JP2010178349 | 2010-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012020767A1 true WO2012020767A1 (ja) | 2012-02-16 |
Family
ID=45567729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/068181 WO2012020767A1 (ja) | 2010-08-09 | 2011-08-09 | ピロロキノリンキノンのゲル |
Country Status (4)
Country | Link |
---|---|
US (1) | US9012521B2 (ja) |
JP (1) | JP5884731B2 (ja) |
CN (1) | CN103052391B (ja) |
WO (1) | WO2012020767A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012137932A1 (ja) * | 2011-04-07 | 2012-10-11 | ロート製薬株式会社 | 外用組成物 |
WO2012165309A1 (ja) * | 2011-05-27 | 2012-12-06 | ロート製薬株式会社 | 外用組成物 |
JP2013006834A (ja) * | 2011-05-25 | 2013-01-10 | Rohto Pharmaceutical Co Ltd | 外用組成物 |
JP2013237644A (ja) * | 2012-05-16 | 2013-11-28 | Mitsubishi Gas Chemical Co Inc | 細胞活性化炭酸水 |
WO2014087990A1 (ja) * | 2012-12-04 | 2014-06-12 | ロート製薬株式会社 | 外用組成物 |
WO2014175327A1 (ja) * | 2013-04-26 | 2014-10-30 | 三菱瓦斯化学株式会社 | 黄色系還元型ピロロキノリンキノン結晶及びその製造方法、並びに、食品、医薬品、ゲル、組成物及び組成物の製造方法 |
US20150272881A1 (en) * | 2011-11-15 | 2015-10-01 | Mitsubishi Gas Chemical Company, Inc. | Reduced pyrroloquinoline quinone gel |
WO2018180885A1 (ja) | 2017-03-28 | 2018-10-04 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン含有ゼリー |
WO2019082550A1 (ja) | 2017-10-25 | 2019-05-02 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン含有グミキャンディ及びその製造方法 |
WO2020045562A1 (ja) * | 2018-08-30 | 2020-03-05 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンの安定化剤、それを含む組成物及び安定化方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10364244B2 (en) | 2015-09-25 | 2019-07-30 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Crystal form of pyrroloquinoline quinone sodium salt and preparation method and use thereof |
ES2788800B2 (es) * | 2019-04-22 | 2021-04-29 | De La Cal Antonio Madronero | Recipiente para acondicionar aceites vegetales mediante la utilización de campos magnéticos y método de aplicación para cosmética. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59113896A (ja) * | 1982-12-17 | 1984-06-30 | Ube Ind Ltd | ピロロキノリンキノンの製造方法 |
WO2006025247A1 (ja) * | 2004-08-30 | 2006-03-09 | Kaneka Corporation | ミトコンドリア賦活剤 |
WO2008023277A2 (en) * | 2006-08-25 | 2008-02-28 | Epc Europe Gmbh | Compositions containing coenzyme q-10 and dihydrolipoic acid |
JP2009185228A (ja) * | 2008-02-08 | 2009-08-20 | Asahi Kasei Chemicals Corp | ゲル化剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2751183B2 (ja) | 1988-02-26 | 1998-05-18 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンの製造方法 |
JP2692167B2 (ja) | 1988-09-01 | 1997-12-17 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン類の回収・精製方法 |
US8283135B2 (en) * | 2000-06-30 | 2012-10-09 | The Procter & Gamble Company | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
WO2005087022A1 (ja) * | 2004-03-12 | 2005-09-22 | Ajinomoto Co., Inc. | 抗ストレス作用を有する食品組成物 |
TW200603786A (en) * | 2004-05-11 | 2006-02-01 | Kaneka Corp | Anti-fatigue composition |
JP2006070016A (ja) * | 2004-08-02 | 2006-03-16 | Kaneka Corp | 還元型補酵素qを含有する美白用組成物 |
US7943189B2 (en) * | 2007-10-26 | 2011-05-17 | Lee Ferrell | Food preservation packaging system |
CN101228963B (zh) * | 2008-01-25 | 2011-09-28 | 上海医学生命科学研究中心有限公司 | 一种含有吡咯并喹啉醌的强化食品 |
WO2009136587A1 (ja) * | 2008-05-08 | 2009-11-12 | 株式会社カネカ | 抗疲労組成物 |
CN101507724A (zh) * | 2008-08-13 | 2009-08-19 | 上海医学生命科学研究中心有限公司 | 吡咯并喹啉醌在抗辐射中的用途 |
-
2011
- 2011-08-09 US US13/814,820 patent/US9012521B2/en active Active
- 2011-08-09 CN CN201180038175.6A patent/CN103052391B/zh active Active
- 2011-08-09 JP JP2012528687A patent/JP5884731B2/ja active Active
- 2011-08-09 WO PCT/JP2011/068181 patent/WO2012020767A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59113896A (ja) * | 1982-12-17 | 1984-06-30 | Ube Ind Ltd | ピロロキノリンキノンの製造方法 |
WO2006025247A1 (ja) * | 2004-08-30 | 2006-03-09 | Kaneka Corporation | ミトコンドリア賦活剤 |
WO2008023277A2 (en) * | 2006-08-25 | 2008-02-28 | Epc Europe Gmbh | Compositions containing coenzyme q-10 and dihydrolipoic acid |
JP2009185228A (ja) * | 2008-02-08 | 2009-08-20 | Asahi Kasei Chemicals Corp | ゲル化剤 |
Non-Patent Citations (1)
Title |
---|
FREDRIC M. MENGER ET AL.: "Anatomy of a Gel. Amino Acid Derivatives That Rigidify Water at Submillimolar Concentrations", J. AM. CHEM. SOC., vol. 122, no. 47, 2000, pages 11679 - 11691, XP055032065, DOI: doi:10.1021/ja0016811 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012137932A1 (ja) * | 2011-04-07 | 2012-10-11 | ロート製薬株式会社 | 外用組成物 |
JP2013006834A (ja) * | 2011-05-25 | 2013-01-10 | Rohto Pharmaceutical Co Ltd | 外用組成物 |
WO2012165309A1 (ja) * | 2011-05-27 | 2012-12-06 | ロート製薬株式会社 | 外用組成物 |
US20150272881A1 (en) * | 2011-11-15 | 2015-10-01 | Mitsubishi Gas Chemical Company, Inc. | Reduced pyrroloquinoline quinone gel |
JP2013237644A (ja) * | 2012-05-16 | 2013-11-28 | Mitsubishi Gas Chemical Co Inc | 細胞活性化炭酸水 |
WO2014087990A1 (ja) * | 2012-12-04 | 2014-06-12 | ロート製薬株式会社 | 外用組成物 |
JP2014131994A (ja) * | 2012-12-04 | 2014-07-17 | Rohto Pharmaceut Co Ltd | 外用組成物 |
CN105189501A (zh) * | 2013-04-26 | 2015-12-23 | 三菱瓦斯化学株式会社 | 黄色系还原型吡咯喹啉醌结晶及其制造方法、以及食品、医药品、凝胶、组合物和组合物的制造方法 |
WO2014175327A1 (ja) * | 2013-04-26 | 2014-10-30 | 三菱瓦斯化学株式会社 | 黄色系還元型ピロロキノリンキノン結晶及びその製造方法、並びに、食品、医薬品、ゲル、組成物及び組成物の製造方法 |
JPWO2014175327A1 (ja) * | 2013-04-26 | 2017-02-23 | 三菱瓦斯化学株式会社 | 黄色系還元型ピロロキノリンキノン結晶及びその製造方法、並びに、食品、医薬品、ゲル、組成物及び組成物の製造方法 |
US9732079B2 (en) | 2013-04-26 | 2017-08-15 | Mitsubishi Gas Chemical Company, Inc. | Yellow reduced pyrroloquinoline quinone crystal and method of producing the same, and food, pharmaceutical, gel, composition and method of producing composition |
WO2018180885A1 (ja) | 2017-03-28 | 2018-10-04 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン含有ゼリー |
KR20190127755A (ko) | 2017-03-28 | 2019-11-13 | 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 | 피롤로퀴놀린퀴논함유 젤리 |
JPWO2018180885A1 (ja) * | 2017-03-28 | 2020-02-06 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン含有ゼリー |
JP7167911B2 (ja) | 2017-03-28 | 2022-11-09 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン含有ゼリー |
WO2019082550A1 (ja) | 2017-10-25 | 2019-05-02 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン含有グミキャンディ及びその製造方法 |
WO2020045562A1 (ja) * | 2018-08-30 | 2020-03-05 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンの安定化剤、それを含む組成物及び安定化方法 |
JPWO2020045562A1 (ja) * | 2018-08-30 | 2021-08-12 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンの安定化剤、それを含む組成物及び安定化方法 |
JP7377442B2 (ja) | 2018-08-30 | 2023-11-10 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンの安定化剤及び安定化方法 |
Also Published As
Publication number | Publication date |
---|---|
US20130203869A1 (en) | 2013-08-08 |
JP5884731B2 (ja) | 2016-03-15 |
CN103052391B (zh) | 2015-04-29 |
JPWO2012020767A1 (ja) | 2013-10-28 |
CN103052391A (zh) | 2013-04-17 |
US9012521B2 (en) | 2015-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5884731B2 (ja) | ピロロキノリンキノンのゲル | |
KR102012305B1 (ko) | 수크로오스와 d-프시코스를 주성분으로 하는 당 조성물 및 그 제조법 | |
WO2012173217A1 (ja) | ピロロキノリンキノンジナトリウム塩の結晶およびその製造方法 | |
TW200831465A (en) | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate | |
TW200810744A (en) | Solid matter containing coenzyme Q | |
JP6052183B2 (ja) | 還元型ピロロキノリンキノンのゲル | |
Wang et al. | Characterizations and microsphere formulation of polysaccharide from the marine clam (Mactra veneriformis) | |
Nasr et al. | Mesoporous silica nanoparticles, a safe option for silymarin delivery: preparation, characterization, and in vivo evaluation | |
KR101694710B1 (ko) | (6s)-5-메틸 테트라히드로 엽산염 결정형 및 그 제조방법 | |
Paul et al. | Curcumin and quercetin as templates in the in vitro biomineralization of CaCO3: A comparative study on phase modulation | |
TW200400043A (en) | A process for the preparation of piroxicam: β -cyclodextrin inclusion compounds | |
JP2004097114A (ja) | ゼリー乾燥物 | |
JP4364869B2 (ja) | 咀嚼性カプセルの製造方法 | |
CN104045679B (zh) | 甘草次酸晶c型、其制备方法及其在药物组合物或保健品中的用途 | |
CN110054606A (zh) | 一种二氢杨梅素-盐酸黄连素药物共晶及制备方法 | |
JP2005325080A (ja) | パントテン酸カルシウム及びビタミン類を含む組成物 | |
CA3058879A1 (en) | Smectite suspension liquid composition and method for preparing same | |
JP2009171903A (ja) | 顆粒状造粒物及びその製造方法 | |
CN110283142B (zh) | 一种非布索坦-吲哚美辛的共无定形物及其制备方法 | |
JP6348024B2 (ja) | 水分散性の良いシリマリン含有組成物 | |
CN108578365B (zh) | 一种虾青素肠内营养乳剂、干乳剂及其制备方法和应用 | |
CN103087138B (zh) | 一种人参皂苷c-k一水合物晶体及制备方法 | |
Kapoor et al. | Konjac Glucomannan: A comprehensive review of its extraction, health benefits, and pharmaceutical applications | |
JP2019519545A (ja) | 変性タウリン及びその製造方法 | |
KR101912525B1 (ko) | 염화칼슘 및 레반으로 코팅한 경구용 제제의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180038175.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11816431 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012528687 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13814820 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11816431 Country of ref document: EP Kind code of ref document: A1 |